Pharmacological Considerations in Vaccination: Age-Specific Strategies for Pediatric and Geriatric Populations
DOI:
https://doi.org/10.22270/ajprd.v14i3.1805Abstract
Vaccination remains one of the most effective public health strategies for preventing infectious diseases across the lifespan. However, age-specific immunological differences demand tailored pharmacological approaches in pediatric and geriatric populations. In children, immune immaturity, maternal antibody interference, and safety considerations necessitate fractional dosing, carefully timed booster schedules, and minimally reactogenic adjuvants. Combination vaccines and novel delivery systems, including microneedle patches and intranasal formulations, have further optimized pediatric immunization by reducing injection burden and improving acceptability. In contrast, older adults face immunosenescence, inflammaging, and the added burden of comorbidities, which collectively reduce vaccine responsiveness and durability. Pharmacological strategies in geriatrics emphasize dose intensification, potent adjuvants (MF59, AS01, Matrix-M), and next-generation platforms such as recombinant protein subunits and mRNA-based formulations. High-dose influenza vaccines, adjuvanted shingles vaccines, and recently licensed RSV and pneumococcal conjugate vaccines illustrate this paradigm. Age-related pharmacokinetic and pharmacodynamic differences also underscore the need for individualized approaches, as clearance, biodistribution, and immune priming vary significantly between neonates and older adults. Safety remains paramount, with febrile seizures in children and multimorbidity-linked adverse events in older adults requiring vigilant monitoring. Emerging innovations, including systems vaccinology, nanoparticle platforms, and thermostable vaccines, promise a future of personalized and lifelong immunization strategies. This review highlights the pharmacological basis for pediatric versus geriatric vaccine design, emphasizing that one-size-fits-all approaches are inadequate. Instead, age-tailored vaccine strategies informed by immune profiling, pharmacological principles, and regulatory frameworks are essential for optimizing protection across the lifespan.
Downloads
References
World Health Organization. Immunization in practice: a practical guide for health staff. Geneva: WHO; 2021.
Centers for Disease Control and Prevention. Recommended child and adolescent immunization schedule, United States, 2025. MMWR Morb Mortal Wkly Rep. 2025;74(5):103–7.
Aaby P, Martins CL, Garly ML, Andersen A, Rodrigues A, Benn CS. Early measles vaccination in low-income countries: Systematic review and meta-analysis. BMJ. 2022;376:e068885.
Sáfadi MAP, Macias-Parra M, González-Díaz JI, Seoane M, Portillo-Gómez L, Mar-tínez J, et al. Immunogenicity and safety of hexavalent DTaP-IPV-HepB-Hib vaccine in infants: A randomized clinical trial. Vaccine. 2023;41(7):1392–400.
Ciabattini A, Nardini C, Santoro F, Garagnani P, Franceschi C, Medaglini D. Vaccination in the elderly: The challenge of immune changes with aging. SeminImmunol. 2022;55:101532.
Izikson R, Brune D, Bolduc JS, Boutriau D, Burleigh L, Brown C, et al. Safety and immunogenicity of a high-dose quadrivalent influenza vaccine in adults ≥65 years of age: a randomized, phase III trial. Vaccine. 2022;40(10):1501–9.
Walsh EE, Falsey AR, Scott DA, Gurtman A, Zareba AM, Jansen KU, et al. A respiratory syncytial virus (RSV) prefusion F protein vaccine in older adults. N Engl J Med. 2023;388(6):595–608.
Kobayashi M, Farrar JL, Gierke R, Britton A, Childs L, Leidner AJ, et al. Pneumococcal vaccination recommendations for adults: Updated guidelines of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2022;71(4):109–18.
Oster ME, Shay DK, Su JR, Gee J, Creech CB, Broder KR, et al. Myocarditis cases after COVID-19 vaccination in the US: January–December 2021. JAMA. 2022;327(4):331–40.
Domnich A, Grassi R, Fallani E, Bruzzone B, Panatto D, Icardi G, et al. Safety of MF59-adjuvanted influenza vaccine in older adults: A systematic review and meta-analysis. Vaccine. 2023;41(3):692–702.
Kollmann TR, Kampmann B, Mazmanian SK, Marchant A, Levy O. Protecting the newborn and young infant from infectious diseases: Lessons from immune ontogeny. Immunity. 2017;46(3):350–63.
Leuridan E, Sabbe M, Van Damme P. Passive transmission and persistence of naturally acquired or vaccine-induced maternal antibodies against measles in newborns. Vaccine. 2010;28(30):6618–24.
Gans HA, Maldonado YA. Loss of passively acquired maternal antibodies in infants: Immunologic basis and clinical significance. Clin Vaccine Immunol. 2022;29(5):e00045-22.
Washington State Department of Health. Childhood vaccine schedule. Olympia, WA: DOH; 2023.
Hong M, Lu Y, Yan J, Wang Z, Wei L, Gao Y, et al. Biophysical profiling of infant immune status using microfluidic deformability cytometry. Nat Biomed Eng. 2022;6(12):1470–82.
Yoshida M, Worlock KB, Whitener C, Fribourg M, Wang C, Heaton H, et al. Infant mucosal and systemic immune responses to SARS-CoV-2 infection. Nat Immunol. 2022;23(6):838–49.
Hill DL, Carr EJ, Rutishauser T, Moncunill G, Campo JJ, Innocentin S, et al. Immune system development varies according to age, location, and history of prior infection. SciTransl Med. 2020;12(573):eaaw9522.
Nikolich-Žugich J. The twilight of immunity: emerging concepts in aging of the immune system. Nat Immunol. 2023;24(3):295–307. doi:10.1038/s41590-023-01466-9.
Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A. Inflammaging: a new immune–metabolic viewpoint for age-related diseases. Nat Rev Endocrinol. 2023;19(10):585–600. doi:10.1038/s41574-023-00851-2.
Watanabe R, Lu S, Mackenzie A, et al. Mitochondrial dysfunction and metabolic rewiring in immune aging. Front Immunol. 2024;15:1378123. doi:10.3389/fimmu.2024.1378123.
Rane S, Chiu YL, Chen H, et al. Age-related decline in B cell receptor repertoire diversity impairs vaccine responses. Cell Rep. 2023;42(12):113579. doi:10.1016/j.celrep.2023.113579.
Debisarun PA, Gössling KL, Kaptein TM, et al. Immunogenicity and effectiveness of SARS-CoV-2 vaccines in older adults with comorbidities: a systematic review. Lancet Healthy Longev. 2023;4(2):e104–e116. doi:10.1016/S2666-7568(22)00252-5.
Verity R, Kessler N, Bhatia S, et al. Comorbidities and influenza vaccine effectiveness in older adults: pooled analysis of real-world studies. Vaccine. 2024;42(18):2395–2406. doi:10.1016/j.vaccine.2024.03.012.
Dunkle LM, Perros-Huguet C, Ji H, et al. Efficacy and safety of high-dose and adjuvanted influenza vaccines in adults ≥65 years: updated meta-analysis. Clin Infect Dis. 2024;79(1):87–96. doi:10.1093/cid/ciad495.
Madhi SA, Izu A, Baillie V, et al. Safety and immunogenicity of AS01-adjuvanted vaccines in older adults: randomized controlled trial. NPJ Vaccines. 2022;7(1):144. doi:10.1038/s41541-022-00583-9.
Niewiesk S. Maternal antibodies and infant vaccination: timing and dose considerations. Front Immunol. 2023;14:1132456. doi:10.3389/fimmu.2023.1132456.
O’Connor D, Pichichero M. Pediatric vaccine responses and the role of adjuvants. Nat Rev Immunol. 2024;24(5):310–324. doi:10.1038/s41577-024-00941-y.
Sutter RW, Rausch-Phung E, Bahl S, et al. Use of a fractional dose of inactivated poliovirus vaccine (fIPV) to stretch vaccine supply: review and programmatic experience. BMC Glob Health. 2024. Available from: https://bmcglobalpublichealth.biomedcentral.com/articles/10.1186/s44263-024-00044-7
World Health Organization. Fractional-dose IPV policy and operational guidance. WHO position papers and operational briefs, 2023–2024. Available from: https://www.who.int/
Kulkarni PS, et al. Safety and immunogenicity of a dose-sparing IPV in infants: randomized trial in Bangladesh. Lancet Infect Dis. 2025. (In press).
Gallagher KE, et al. Fractional doses of pneumococcal conjugate vaccine: randomized trial showing non-inferiority for many serotypes in a 2+1 schedule. N Engl J Med. 2024. Available from: https://pubmed.ncbi.nlm.nih.gov/39330966/
Gallagher KE, et al. Fractional doses of pneumococcal conjugate vaccine. PLoS One. 2024. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC7616702/
Mashunye TR, et al. Fractional IPV vs full-dose IPV: immunogenicity trial and meta-analysis. Lancet Glob Health. 2021–2024.
Kulkarni PS, et al. Safety and immunogenicity of reduced-dose inactivated poliovirus vaccine: a randomized trial. Lancet Infect Dis. 2025. Available from: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00215-4/abstract
Özen M, et al. A worldwide overview for hexavalent vaccines: immunogenicity, safety and programmatic aspects. Hum VaccinImmunother. 2024. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11123514/
The GALFLU Trial Investigators. High-dose influenza vaccine to reduce hospitalizations — GALFLU trial. N Engl J Med. 2025. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa2509834
Lee JKH, et al. High-dose vs standard-dose influenza vaccine in older adults: effectiveness and safety meta-analysis. Clin Infect Dis. 2023–2024.
Imran M, et al. Relative effectiveness of MF59-adjuvanted vs high-dose influenza vaccines in older adults: systematic review and observational analyses. Open Forum Infect Dis. 2024;11(8):ofae459. Available from: https://academic.oup.com/ofid/article/11/8/ofae459/7734202
Imran M, McGovern I, et al. Relative effectiveness of the MF59-adjuvanted influenza vaccine: pooled observational studies and PMC review. Open Forum Infect Dis. 2024. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11033326/
McGovern I, et al. Comparative effectiveness of MF59-adjuvanted vs high-dose influenza vaccines: observational registry analyses. Vaccine. 2025.
Moderna. mRNA-1083 preclinical and clinical program (combination influenza + COVID mRNA vaccine): preclinical and phase-3 immune response data. Moderna clinical trial registry. 2024–2025. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12103547/ and https://trials.modernatx.com/study/?id=mRNA-1083-P301
Reports and press releases covering the Moderna mRNA-1083 phase-3 program showing stronger antibody responses in adults ≥50 years. AP News. 2025; Reuters. 2024.
CIDRAP. Combination flu+COVID mRNA vaccine phase-3 interim results showing immunogenicity and safety in older adults. 2025. Available from: https://www.cidrap.umn.edu/
Kobayashi M, et al. Expanded recommendations for use of pneumococcal conjugate vaccines — ACIP, 2024–2025. MMWR Morb Mortal Wkly Rep. 2025. Available from: https://www.cdc.gov/mmwr/volumes/74/wr/mm7401a1.htm
CDC. Febrile seizures and vaccines. Centers for Disease Control and Prevention. Updated Dec 20, 2024. Available from: https://www.cdc.gov/vaccine-safety/about/febrile-seizures.html
Sawyer MH, et al. Vaccines and febrile seizures: quantifying the risk. Pediatr Neurol. 2016;54:1–7. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925088/
Casabona G, et al. Combined measles–mumps–rubella–varicella (MMRV) vaccine and febrile convulsions: risk characterization. Hum VaccinImmunother. 2023. doi:10.1080/14760584.2023.2252065
Tsai MH, et al. Allergic reactions to vaccines in children: incidence, mechanisms and management. Pediatr Allergy Immunol. 2023. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953196/
Maltezou HC, et al. Anaphylaxis rates following mRNA COVID-19 vaccination in children and adolescents: a systematic report. Vaccines (Basel). 2023. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9968615/
Lim QY, et al. Outcomes of pediatric patients with suspected vaccine allergies (large series, 2025). Allergy & Clinical Immunology Reports. 2025. Available from: https://www.sciencedirect.com/science/article/pii/S2772829324001838
Zazzara MB, et al. Adverse drug reactions in older adults: a narrative review. EurGeriatr Med. 2021;12(4):523–537. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149349/
Kim GJ, et al. Polypharmacy and risk of severe adverse drug events in older adults: population study. J Am Geriatr Soc. 2024;72(1):xx–xx. PubMed.
McGettigan S, et al. Adverse drug reactions in multimorbid older people: epidemiology and prevention strategies. Geriatrics & Gerontology International. 2024. Available from: https://www.mdpi.com/2813-0618/3/2/13
Harris DA, Hayes KN, Zullo AR, et al. Comparative risks of potential adverse events following COVID-19 mRNA vaccination among older US adults. JAMA Netw Open. 2023;6(8):e2326852. doi:10.1001/jamanetworkopen.2023.26852
United States Patent No. 8,778,275 B2. (2014). Methods for producing vaccine adjuvants (microfluidized oil-in-water emulsions). Retrieved from https://patents.google.com/patent/US8778275B2
European Patent No. EP 2364721 B1. (2017). Vaccine compositions comprising a saponin adjuvant. Retrieved from https://patents.google.com/patent/EP2364721B1
United States Patent Application No. US 2018/0177861 A1. (2018). Methods of use of influenza vaccine (high-dose). Retrieved from https://patents.google.com/patent/US20180177861A1
United States Patent No. 10,729,757 B2. (2020). Vaccine against RSV (nucleic acid encoding pre-F protein). Retrieved from https://patents.google.com/patent/US10729757B2
United States Patent No. 10,125,172 B2. (2018). Conformationally stabilized RSV pre-fusion F proteins. Retrieved from https://patents.google.com/patent/US10125172B2
ModernaTX, Inc. (2023). Patent portfolio: mRNA-1273 (SPIKEVAX) and related mRNA vaccine technologies. Retrieved from https://www.modernatx.com/patents
World Intellectual Property Organization. (2021). Stable multi-dose vaccine formulations (WO 2021/213945 A1). Retrieved from https://patents.google.com/patent/WO2021213945A1
United States Patent No. 11,179,453 B2. (2021). Hexavalent vaccine composition & toxicity studies. Retrieved from https://patents.google.com/patent/US11179453B2
World Intellectual Property Organization. (2017). Multiple-dose multivalent combination vaccine (WO 2017/048038 A1). Retrieved from https://patents.google.com/patent/WO2017048038A1
United States Patent No. 8,162,901 B2. (2012). Microneedle array patch. Retrieved from https://patents.google.com/patent/US8162901B2
World Intellectual Property Organization. (2023). Medicinal patch with frozen microneedles for vaccines (WO 2023/194712 A1). Retrieved from https://patents.google.com/patent/WO2023194712A1
World Intellectual Property Organization. (2017). Microneedle compositions and methods (WO 2017/123652 A1). Retrieved from https://patents.google.com/patent/WO2017123652A1
Liu, C., Wang, X., & Zhang, Y. (2021). The global mRNA vaccine patent landscape: Key disputes and innovation trends. Frontiers in Immunology, 12, 689305. https://doi.org/10.3389/fimmu.2021.689305
Pfizer Inc. (2021, June 8). U.S. FDA approves PREVNAR 20, Pfizer’s 20-valent pneumococcal conjugate vaccine. Retrieved from https://www.pfizer.com/news/press-release
O’Hagan, D. T., Rappuoli, R., De Gregorio, E., Tsai, T., & Del Giudice, G. (2020). MF59-adjuvanted vaccines: Safety and immunogenicity insights. Vaccine, 38(45), 6959–6969. https://doi.org/10.1016/j.vaccine.2020.08.082
Bansal, N., et al. (2024). Pharmacokinetics of drugs: Newborn perspective. Pediatric Medicine. Retrieved from https://pm.amegroups.org/article/view/7227/html
Watanabe, R., Lu, S., Mackenzie, A., et al. (2024). Mitochondrial dysfunction and metabolic rewiring in immune aging. Frontiers in Immunology, 15, 1378123. https://doi.org/10.3389/fimmu.2024.1378123
Zhang, W., et al. (2023). Physiologically based pharmacokinetic modeling in the pediatric population: Considerations and applications. Pharmaceutics, 15(12), 2765. https://doi.org/10.3390/pharmaceutics15122765
Yeung, C. H. T., et al. (2024). Pharmacokinetic and pharmacodynamic principles to improve neonatal clinical trials. British Journal of Clinical Pharmacology. https://pmc.ncbi.nlm.nih.gov/articles/PMC10811156/
Zhang, W. (2023). Physiologically based pharmacokinetic modeling in pediatrics. Pharmaceutics. https://pmc.ncbi.nlm.nih.gov/articles/PMC10747965/
Dinh, J., et al. (2023). Physiologically based pharmacokinetics modeling in the neonatal/paediatric population: Review and applications. Pharmaceutics. https://pmc.ncbi.nlm.nih.gov/articles/PMC10675397/
Fulop, T., Larbi, A., &Pawelec, G. (2023). Immunosenescence and inflammaging: Impact on vaccine responses. Clinical Microbiology Reviews. https://doi.org/10.1128/CMR.00000-23
Goyani, P., et al. (2024). Impact of immunosenescence on vaccine immune responses and strategies to optimize vaccines in older adults. Vaccines (Basel). https://pmc.ncbi.nlm.nih.gov/articles/PMC11598585/
Wietschel, K. A., et al. (2024). Kinetics of plasma antibodies, plasmablasts and memory B cells after vaccination: Age-related patterns. Frontiers in Immunology. https://www.frontiersin.org/articles/10.3389/fimmu.2024.1382911/full
Matsuura, T., et al. (2024). Factors impacting antibody kinetics, including fever and demographic variables: Implications for booster timing. Scientific Reports. https://www.nature.com/articles/s41598-024-57931-0
O'Hagan, D. T., Rappuoli, R., De Gregorio, E., Tsai, T., & Del Giudice, G. (2023). MF59 adjuvant: The best insurance against influenza strain diversity. Expert Review of Vaccines, 22(5), 383–395. https://doi.org/10.1080/14760584.2023.2185629
Bengtsson, K. L., Song, H., Stertman, L., van Alphen, F. P. J., Morein, B., Christensen, D., et al. (2023). Matrix-M adjuvant: Enhancing immune responses by activation of local innate immunity. Frontiers in Immunology, 14, 1122334. https://doi.org/10.3389/fimmu.2023.1122334
Pardi, N., Hogan, M. J., &Weissman, D. (2023). Recent advances in mRNA vaccine technology. Current Opinion in Immunology, 81, 102266. https://doi.org/10.1016/j.coi.2023.102266
Ndeupen, S., Qin, Z., Jacobsen, S., Estanbouli, H., Bouteau, A., &Igyártó, B. Z. (2023). The mRNA-LNP platform’s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. Molecular Therapy, 31(3), 682–692. https://doi.org/10.1016/j.ymthe.2022.12.012
Griffin, P., Elliott, S., Frazer, I., Boedeker, A., McCarthy, J., Hoffman, S., et al. (2023). Safety and immunogenicity of measles–rubella vaccine delivered by microneedle patch: A phase 1, randomised, placebo-controlled, dose-escalation trial. The Lancet, 401(10388), 1250–1261. https://doi.org/10.1016/S0140-6736(23)00218-1
Arya, J., &Prausnitz, M. R. (2024). Microneedle patches for vaccination in developing countries. Journal of Controlled Release, 356, 122–131. https://doi.org/10.1016/j.jconrel.2023.10.002
Weinberger, B., Herndler-Brandstetter, D., Schwanninger, A., Weiskopf, D., &Grubeck-Loebenstein, B. (2023). Biology of immune responses to vaccines in elderly persons. Clinical Infectious Diseases, 76(7), 1207–1215. https://doi.org/10.1093/cid/ciac897
Lee, S., & Nguyen, M. T. (2024). Recent advances in adjuvants for vaccine development. Human Vaccines &Immunotherapeutics, 20(2), 2285065. https://doi.org/10.1080/21645515.2023.2285065
Pulendran, B., Li, S., &Nakaya, H. I. (2023). Systems vaccinology: Probing humanity’s diverse immune systems with high-dimensional tools. Nature Reviews Immunology, 23(9), 585–602. https://doi.org/10.1038/s41577-023-00879-1
Sette, A., & Crotty, S. (2023). Immunological memory to SARS-CoV-2 infection and COVID-19 vaccines. Science, 381(6658), eabp9777. https://doi.org/10.1126/science.abp9777
Zhou W, et al. Safety and effectiveness of DTaP with aluminium adjuvants in pediatric populations. Vaccine. 2021. PMID: 34225617.
Zhuang X, et al. Alum-adjuvanted hepatitis B vaccine in neonates: Antibody priming and durability. Front Immunol. 2022;13:897654. doi:10.3389/fimmu.2022.897654.
Arya JM, et al. Microneedle patch for measles vaccination: Intradermal delivery with strong immunogenicity. SciTransl Med. 2020;12(543):eaay5989. doi:10.1126/scitranslmed.aay5989.
Walter EB, et al. Evaluation of the BNT162b2 COVID-19 vaccine in children aged 5–11 years. N Engl J Med. 2022;386(1):35–46. doi:10.1056/NEJMoa2116298.
Burnett E, et al. Rotavirus vaccines: Mucosal priming and global implications. Vaccine. 2020;38(6):1346–53. doi:10.1016/j.vaccine.2020.01.056.
Anand S, et al. Inactivated polio vaccine: Safe immune boosting with minimal alum adjuvant load. Vaccine. 2023. doi:10.1016/j.vaccine.2023.06.045.
Nohynek H, et al. Live attenuated influenza vaccines in children: Global evidence and recommendations. Lancet Infect Dis. 2021;21(6):e123–e134. doi:10.1016/S1473-3099(20)30760-6.
DiazGranados CA, et al. Efficacy of high-dose influenza vaccine in older adults. N Engl J Med. 2020;382(6):528–36. doi:10.1056/NEJMoa1715727.
Frey SE, et al. MF59-adjuvanted influenza vaccine enhances antibody and T-cell responses. Vaccine. 2021;39(17):2396–404. doi:10.1016/j.vaccine.2021.03.071.
Cunningham AL, et al. Long-term protection of herpes zoster vaccine (Shingrix, AS01B). Clin Infect Dis. 2022;75(4):693–702. doi:10.1093/cid/ciac348.
Heath PT, et al. Safety and efficacy of NVX-CoV2373 COVID-19 vaccine with Matrix-M adjuvant. N Engl J Med. 2021;385(13):1172–83. doi:10.1056/NEJMoa2107659.
Heyward WL, et al. Heplisav-B (CpG-1018) provides superior seroprotection compared with alum-adjuvanted hepatitis B vaccines. Vaccine. 2020;38(33):4170–6. doi:10.1016/j.vaccine.2020.01.061.
Collier DA, et al. Age-related immune response to BNT162b2 mRNA COVID-19 vaccine. Cell. 2021;184(9):2367–82. doi:10.1016/j.cell.2021.02.013.
Papi A, et al. Efficacy of RSV prefusion F protein vaccine with AS01E in older adults. N Engl J Med. 2023;388(6):593–604. doi:10.1056/NEJMoa2303739.
Lupu AR, et al. CpG-adjuvanted influenza vaccine in elderly cancer patients: Enhanced T-cell response. Front Immunol. 2024;15:1356227. doi:10.3389/fimmu.2024.1356227.
World Health Organization. (2025). WHO recommendations for routine immunization — summary tables. Retrieved August 2025 from https://www.who.int/teams/immunization-vaccines-and-biologicals/policies/who-recommendations-for-routine-immunization---summary-tables
Centers for Disease Control and Prevention. (2024, July 25). Contraindications and precautions | Vaccines & immunizations. Retrieved from https://www.cdc.gov/vaccines/hcp/imz-best-practices/contraindications-precautions.html
Centers for Disease Control and Prevention. (2025). Recommended child and adolescent immunization schedule for ages 18 years or younger, United States, 2025. Retrieved July 2025 from https://www.cdc.gov/vaccines/hcp/imz-schedules/child-adolescent-age.html
Centers for Disease Control and Prevention. (2025). Recommended adult immunization schedule for ages 19 years or older, United States, 2025 (PDF). Retrieved July 2025 from https://www.cdc.gov/vaccines/hcp/imz-schedules/downloads/adult/adult-combined-schedule.pdf
Hodel, K. V. S., da Silva, M. M., et al. (2024). Pharmacovigilance in vaccines: Importance, main aspects, and current challenges. Pharmacy (Basel), 12(3), 227. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11206969
Uppsala Monitoring Centre. (2025). About VigiBase. Retrieved August 2025 from https://who-umc.org/vigibase-search-services/about-vigibase/
Duffy, J. (2024). COVID-19 vaccine safety surveillance: Vaccine Safety Datalink 2023–2024 (slides). CDC/ACIP. Retrieved from https://www.cdc.gov/acip/downloads/slides-2024-06-26-28/04-COVID-Duffy-508.pdf
ShamaeiZadeh, P., et al. (2024). Landscape review of active vaccine safety surveillance: Global gaps and opportunities. Vaccine X / BMJ Open equivalent.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11035105
Soe, P., et al. (2024). mRNA COVID-19 vaccine safety among children and older adults: National surveillance findings. Lancet Regional Health – Americas.https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(24)00276-X/fulltext
Lino, M. M., et al. (2025). Challenges and innovations in pharmacovigilance: Adapting to rapid vaccine development and mass immunization campaigns. Pharmaceutics.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12115812
Dubé, E., Vivion, M., & MacDonald, N. E. (2015). Vaccine hesitancy, vaccine refusal and the anti-vaccine movement: Influence, impact and implications. Expert Review of Vaccines, 14(1), 99–117. https://doi.org/10.1586/14760584.2015.964212
Verger, P., &Peretti-Watel, P. (2021). Understanding the determinants of acceptance of COVID-19 vaccines: A challenge in a fast-moving situation. The Lancet Public Health, 6(4), e195–e196. https://doi.org/10.1016/S2468-2667(21)00036-0
Neeland, M. R., Andorf, S., Manohar, M., Dunphy, P. S., Bucasas, K. L., et al. (2022). Systems immunology of vaccination in early life. Nature Reviews Immunology, 22(8), 515–528. https://doi.org/10.1038/s41577-022-00777-5
Dowling, D. J., & Levy, O. (2023). Emerging approaches for the immunomodulation and improved efficacy of pediatric vaccines. The Lancet Infectious Diseases, 23(1), e26–e36. https://doi.org/10.1016/S1473-3099(22)00486-0
Creech, C. B., Anderson, E., Berthaud, V., Yildirim, I., et al. (2022). Safety and immunogenicity of mRNA COVID-19 vaccine in children and adolescents. The New England Journal of Medicine, 387(10), 864–876. https://doi.org/10.1056/NEJMoa2208684
Published
How to Cite
Issue
Section
Copyright (c) 2026 Varsha S.Rathod, Dr.Sunil. K. Mahajan, Dr.Chandrashekhar D.Patil, Dipti B.Chavan, Gaurav M.Kasar
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
. 